AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39656510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile step-tracking app intervention (EG)
Number of subjects: 50
Study 39656510 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 39656600 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg, intravenously) on Day 1 combined with XELOX (oxaliplatin at 130 mg/m2 and capecitabine)
Number of subjects: 0
Study 39656628 — intervention group
Group type: EXPERIMENTAL
Intervention: Runcaciguat (30-120 mg once daily, titrated weekly)
Number of subjects: 243
Study 39656628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 39656748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 3012
Study 39656748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3012
Study 39656830 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 1190
Study 39656933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eye drops twice daily for 4 weeks
Number of subjects: 2500
Study 39656933 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops twice daily for 4 weeks
Number of subjects: 2500
Study 39656933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eye drops
Number of subjects: 2500
Study 39656933 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 2500
Study 39656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET)
Number of subjects: 4048
Study 39656951 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus ET
Number of subjects: 4048
Study 39657126 — intervention group
Group type: COMPARATOR
Intervention: Private institutions
Number of subjects: 1029
Study 39657126 — intervention group
Group type: COMPARATOR
Intervention: Public institutions
Number of subjects: 1029
Study 39657168 — intervention group
Group type: EXPERIMENTAL
Intervention: LARKSPUR (web-based PA regulation intervention)
Number of subjects: 95
Study 39657168 — intervention group
Group type: COMPARATOR
Intervention: emotion reporting/attention control
Number of subjects: 95
Study 39657177 — intervention group
Group type: EXPERIMENTAL
Intervention: Presage Care monitoring system
Number of subjects: 118
Study 39657179 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tea Meditation (GTM)
Number of subjects: 100
Study 39657179 — intervention group
Group type: COMPARATOR
Intervention: Breathing Meditation (BM)
Number of subjects: 100
Study 39657205 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing device
Number of subjects: 95
Study 39657205 — intervention group
Group type: COMPARATOR
Intervention: Standard clamping and suturing techniques
Number of subjects: 95
Study 39657224 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen strategy (arterial oxygen saturation target of 94%)
Number of subjects: 1979
Study 39657224 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen strategy (12-15 L of oxygen per minute or fraction of inspired oxygen of 0.6-1.0)
Number of subjects: 1979
Study 39657224 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen strategy
Number of subjects: 1979
Study 39657224 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen strategy
Number of subjects: 1979
Study 39657458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 0
Study 39657458 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum hip extension
Number of subjects: 0
Study 39657575 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (palbociclib 125 mg on days 1-21 and letrozole 2.5 mg on days 1-28)
Number of subjects: 77
Study 39657575 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole (placebo on days 1-21 and letrozole 2.5 mg on days 1-28)
Number of subjects: 77
Study 39657575 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 77
Study 39657575 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 77
Study 39657693 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary antiretroviral therapy (ART)
Number of subjects: 93
Study 39657693 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiomic analysis
Number of subjects: 93
Study 39657693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidomic analysis
Number of subjects: 93
Study 39657760 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sport participation
Number of subjects: 184
Study 39657760 — intervention group
Group type: COMPARATOR
Intervention: Individual physical activity
Number of subjects: 184
Study 39657760 — intervention group
Group type: COMPARATOR
Intervention: Control condition (date night)
Number of subjects: 184
Study 39657845 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant message rehabilitation intervention over six months in addition to standard care
Number of subjects: 0
Study 39657845 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation
Number of subjects: 0
Study 39657845 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant message rehabilitation intervention
Number of subjects: 0
Study 39657981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 1766
Study 39657981 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 1766
Study 39657989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 571
Study 39657989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 39658013 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered empowerment model intervention
Number of subjects: 68
Study 39658013 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 68
Study 39658198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare 22q11.2 copy number variants (CNVs) detected through whole genome microarray genotyping.
Number of subjects: 272
Study 39658198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare 22q11.2 CNVs
Number of subjects: 272
Study 39658198 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV screening
Number of subjects: 272
Study 39658198 — intervention group
Group type: COMPARATOR
Intervention: CNV burden in EBAV cohort
Number of subjects: 272
Study 39658277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) administration in high-risk pregnancies
Number of subjects: 58
Study 39658277 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (previous study comparison group)
Number of subjects: 58
Study 39658315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood pressure target (77 mmHg)
Number of subjects: 789
Study 39658315 — intervention group
Group type: COMPARATOR
Intervention: Lower blood pressure target (63 mmHg)
Number of subjects: 789
Study 39658326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1g on days 1, 15, and 180±7)
Number of subjects: 37
Study 39658326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 39658326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 37
Study 39658608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating modified CAPOX (capecitabine 1000 mg/m² and oxaliplatin) plus bevacizumab (anti-VEGF-A antibody)
Number of subjects: 0
Study 39658608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody)
Number of subjects: 0
Study 39658784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored internet-delivered cognitive behavior therapy (ICBT) for 10 weeks
Number of subjects: 101
Study 39658784 — intervention group
Group type: COMPARATOR
Intervention: Active control group (non-directive support) for 10 weeks
Number of subjects: 101
Study 39658862 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic sepsis screening
Number of subjects: 60055
Study 39658862 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 60055
Study 39659090 — intervention group
Group type: EXPERIMENTAL
Intervention: MV-PCI
Number of subjects: 8138
Study 39659090 — intervention group
Group type: COMPARATOR
Intervention: CV-PCI
Number of subjects: 8138
Study 39659276 — intervention group
Group type: EXPERIMENTAL
Intervention: active rTMS + active rSMS
Number of subjects: 42
Study 39659276 — intervention group
Group type: COMPARATOR
Intervention: active rTMS + sham rSMS
Number of subjects: 42
Study 39659429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary or pharmacologic iron restriction
Number of subjects: 0
Study 39659429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evidence from case reports and small case series studies
Number of subjects: 0
Study 39659870 — intervention group
Group type: EXPERIMENTAL
Intervention: Application Plus Online Therapist Support Group (AT + OT Group)
Number of subjects: 105
Study 39659870 — intervention group
Group type: EXPERIMENTAL
Intervention: Application Only Group (Group A)
Number of subjects: 105
Study 39659870 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group (WLC Group)
Number of subjects: 105
Study 39660140 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine
Number of subjects: 26
Study 39660637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (anti-interleukin-5 monoclonal antibody)
Number of subjects: 0
Study 39660637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39660725 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min pegboard and ring test (6PBRT)
Number of subjects: 22
Study 39660783 — intervention group
Group type: EXPERIMENTAL
Intervention: CMD-positive patients
Number of subjects: 262
Study 39660834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Number of subjects: 874
Study 39660834 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 874
Study 39660834 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant-abemaciclib
Number of subjects: 874
Study 39660861 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg subcutaneously weekly after step-up dosing
Number of subjects: 26
Study 39661074 — intervention group
Group type: EXPERIMENTAL
Intervention: Social risk factors (SRFs) affecting care
Number of subjects: 100
Study 39661074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income participants
Number of subjects: 100
Study 39661074 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants lost to follow-up (LTFU)
Number of subjects: 100
Study 39661074 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility as a P-T domain
Number of subjects: 100
Study 39661074 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to appointment as an SRF
Number of subjects: 100
Study 39661119 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/day
Number of subjects: 3668
Study 39661119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3668
Study 39661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheimpflug imaging (Pentacam HR, Oculus)
Number of subjects: 81
Study 39661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Swept source AS-OCT (Casia SS-1000 Tomey)
Number of subjects: 81
Study 39661178 — intervention group
Group type: COMPARATOR
Intervention: Both devices (Scheimpflug and AS-OCT)
Number of subjects: 81
Study 39661358 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab treatment
Number of subjects: 211
Study 39661372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg per day)
Number of subjects: 558
Study 39661372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 558
Study 39661372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study 39661440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) session of 30 minutes
Number of subjects: 327
Study 39661440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 327
Study 39661440 — intervention group
Group type: COMPARATOR
Intervention: Control group without added MI
Number of subjects: 327
Study 39661851 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study
Number of subjects: 415
Study 39661923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD)
Number of subjects: 40
Study 39661957 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month, mobile phone-delivered, family-focused, self-care support intervention
Number of subjects: 318
Study 39661957 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 318
Study 39661964 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled long-acting beta-2 agonists (LABAs)
Number of subjects: 0
Study 39661964 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta-2 agonists (SABAs)
Number of subjects: 0
Study 39661964 — intervention group
Group type: COMPARATOR
Intervention: Non-LABA users
Number of subjects: 0
Study 39661964 — intervention group
Group type: EXPERIMENTAL
Intervention: Days SABAs were used
Number of subjects: 0
Study 39662163 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicinumab 100 mg/kg intravenously once every 4 weeks from baseline to Week 20
Number of subjects: 52
Study 39662163 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously once every 4 weeks from baseline to Week 20
Number of subjects: 52
Study 39662163 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicinumab (mfVEP substudy)
Number of subjects: 52
Study 39662163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mfVEP substudy)
Number of subjects: 52
Study 39662163 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicinumab
Number of subjects: 52
Study 39662163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 39662304 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT (5.3 g of CIT)
Number of subjects: 43
Study 39662304 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA (5.3 g of CIT, 2.7 g of malate)
Number of subjects: 43
Study 39662304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 39662486 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine with rituximab
Number of subjects: 39
Study 39662676 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food supplements (CFSs) with caregiver nutrition counseling
Number of subjects: 0
Study 39662676 — intervention group
Group type: COMPARATOR
Intervention: Control group (counseling alone)
Number of subjects: 0
Study 39662676 — intervention group
Group type: EXPERIMENTAL
Intervention: CFSs
Number of subjects: 0
Study 39662698 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 132
Study 39662698 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine ER
Number of subjects: 132
Study 39663002 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing frequency of one time per year
Number of subjects: 201
Study 39663002 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing frequency of two times per year
Number of subjects: 201
Study 39663002 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing frequency of three times per year
Number of subjects: 201
Study 39663060 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Clip transcatheter tricuspid annuloplasty system
Number of subjects: 96
Study 39663161 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend-PE model (structured integrated post-pulmonary embolism follow-up care model)
Number of subjects: 2000
Study 39663161 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2000
Study 39663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor-psoas tenotomy + Temporary Medial Hemiepiphysiodesis of the Proximal Femur (TMH-PF)
Number of subjects: 0
Study 39663160 — intervention group
Group type: COMPARATOR
Intervention: Adductor-psoas tenotomy
Number of subjects: 0
Study 39663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor-psoas tenotomy + TMH-PF
Number of subjects: 0
Study 39663170 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation combined with ERAS (PREERAS) management
Number of subjects: 164
Study 39663170 — intervention group
Group type: COMPARATOR
Intervention: Regular preadmission education and perioperative ERAS care
Number of subjects: 164
Study 39663172 — intervention group
Group type: COMPARATOR
Intervention: Debridement of central or radial tear
Number of subjects: 0
Study 39663172 — intervention group
Group type: COMPARATOR
Intervention: Repair of peripheral tear
Number of subjects: 0
Study 39663175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 719
Study 39663175 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 719
Study 39663378 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltorexant 20 mg
Number of subjects: 0
Study 39663378 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg
Number of subjects: 0
Study 39663378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39663512 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Number of subjects: 24
Study 39663512 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 39663544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala coloring plus antenatal education
Number of subjects: 140
Study 39663544 — intervention group
Group type: COMPARATOR
Intervention: Antenatal education alone
Number of subjects: 140
Study 39663755 — intervention group
Group type: EXPERIMENTAL
Intervention: Care4Today Connect (C4T CAD-PAD) mobile application
Number of subjects: 271
Study 39664091 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by midwives (theoretical and practical knowledge)
Number of subjects: 53
Study 39664091 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by midwives (breastfeeding management)
Number of subjects: 53
Study 39664091 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by midwives (self-esteem and commitment)
Number of subjects: 53
Study 39664091 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives' motivation to use appropriate teaching strategies
Number of subjects: 53
Study 39664231 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (1 or 2 mg once daily)
Number of subjects: 2484
Study 39664231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2484
Study 39664752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (2,000 mg per day)
Number of subjects: 82
Study 39664752 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study 39664767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling intervention (six theoretical and practical workshops on food and nutrition education over 4 months)
Number of subjects: 158
Study 39664767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 158
Study 39664835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraconservative treatment (UCT)
Number of subjects: 135
Study 39664835 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 135
Study 39664835 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 135
Study 39665054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitalthings Guardian M10 (contactless patient monitor)
Number of subjects: 32
Study 39665054 — intervention group
Group type: COMPARATOR
Intervention: Nox T3s (reference device)
Number of subjects: 32
Study 39665235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-001.1 15 mg
Number of subjects: 51
Study 39665235 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 30 mg
Number of subjects: 51
Study 39665235 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 20 mg twice-daily
Number of subjects: 51
Study 39665235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-001.1 5, 10 or 15 mg twice-daily for 4 days
Number of subjects: 51
Study 39665235 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 15 mg
Number of subjects: 51
Study 39665378 — intervention group
Group type: COMPARATOR
Intervention: Implementation strategies (e.g. educational materials, educational meetings, education outreach visits)
Number of subjects: 6489
Study 39665482 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-slot brackets with an integral base
Number of subjects: 100
Study 39665482 — intervention group
Group type: COMPARATOR
Intervention: Conventional twin brackets with foil mesh
Number of subjects: 100
Study 39665482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracket removal pliers
Number of subjects: 100
Study 39665482 — intervention group
Group type: COMPARATOR
Intervention: Lift-Off Debonding Instrument
Number of subjects: 100
Study 39665482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive removal methods involving rotary instruments
Number of subjects: 100
Study 39665506 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 59
Study 39665506 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 59
Study 39665506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 39665575 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for metabolic acidosis
Number of subjects: 0
Study 39665575 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39665585 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring (follow-up every 6 months with breast imaging and physical examination; n=484)
Number of subjects: 995
Study 39665585 — intervention group
Group type: COMPARATOR
Intervention: Guideline-concordant care (surgery with or without radiation therapy; n=473)
Number of subjects: 995
Study 39665585 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 995
Study 39665585 — intervention group
Group type: COMPARATOR
Intervention: Guideline-concordant care
Number of subjects: 995
Study 39665588 — intervention group
Group type: COMPARATOR
Intervention: Guideline-concordant care (GCC)
Number of subjects: 957